person · Reporting owner
GAROFALO ELIZABETH A.
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2026 | June 01, 2026 |
| Alector, Inc.ALEC · Entity 6051 | Director | June 17, 2026 | June 17, 2026 |
| EXICURE, INC.XCUR · Entity 8068 | Director | June 13, 2022 | June 15, 2022 |
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | June 01, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,489 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 33,489 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,311 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28 | Direct | 16,004 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Alector, Inc.
Report date June 17, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 118,650 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 28,700 · Balance 118,650 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-06-16 | Direct | 9,450 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 9,450 · Balance 9,450 F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders.
EXICURE, INC.
Report date June 13, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.13 · Expires 2032-06-12 | Direct | 50,000 |
Reported balance
After 2022-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-13 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date.
Xenon Pharmaceuticals Inc.
Report date June 01, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 2,645 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Exercise / conversion · Acquired 2,645 · Balance 2,645 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Exercise / conversion · Disposed 2,645 · Balance 0 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,593 |
Reported balance
After 2026-06-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-03 · Grant · Acquired 1,593 · Balance 1,593 F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.46 · Expires 2036-06-02 | Direct | 10,507 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 10,507 · Balance 10,507 F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 17, 2026 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 9,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274132 · ownership.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 9,450 shares Expires 2036-06-16 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 28,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274132 · ownership.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,650 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:04 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 1,593 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-256122 · ownership.xml · derivative · entry 4 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,593 Underlying: Common Shares · 1,593 shares Expires not disclosed F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:04 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 10,507 | $0.00 Strike: $53.46 | $0.00 |
DisclosureSEC source: 0001193125-26-256122 · ownership.xml · derivative · entry 3 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,507 Underlying: Common Shares · 10,507 shares Expires 2036-06-02 F2 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:04 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionRestricted Share Units · Derivative | 2,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-256122 · ownership.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · derivative.exercise_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · derivative.expiration_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:04 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-256122 · ownership.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001826361-26-000002 · form4-06012026_060603.xml · derivative · entry 4 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,311 Underlying: Common Stock · 9,311 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 16,004 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001826361-26-000002 · form4-06012026_060603.xml · derivative · entry 3 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,004 Underlying: Common Stock · 16,004 shares Expires 2036-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 8,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001826361-26-000002 · form4-06012026_060603.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001826361-26-000002 · form4-06012026_060603.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,600 | $25.98 | $41,560.48 |
DisclosureSEC source: 0001415889-25-023592 · form4-09032025_060901.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,382 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.97 to $25.991, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 9,450 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0000950170-25-085618 · ownership.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 9,450 shares Expires 2035-06-10 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 11, 2025, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 28,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085618 · ownership.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,950 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 11, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:59 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 2,645 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083323 · ownership.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,645 Underlying: Common Shares · 2,645 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:59 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 17,012 | $0.00 Strike: $30.73 | $0.00 |
DisclosureSEC source: 0000950170-25-083323 · ownership.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,012 Underlying: Common Shares · 17,012 shares Expires 2035-06-04 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015272 · form4-06022025_060605.xml · derivative · entry 4 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,107 Underlying: Common Stock · 8,107 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 13,793 | $0.00 Strike: $22.29 | $0.00 |
DisclosureSEC source: 0001415889-25-015272 · form4-06022025_060605.xml · derivative · entry 3 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,793 Underlying: Common Stock · 13,793 shares Expires 2035-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015272 · form4-06022025_060605.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,387 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:05 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015272 · form4-06022025_060605.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 23:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 4,919 | $18.23 | $89,673.37 |
DisclosureSEC source: 0001415889-25-007299 · form4-03062025_060312.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,595 Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 20:46 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-072516 · ownership.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,250 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 12, 2025 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 05, 2024 Filed Jun 5, 2024 21:42 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 15,542 | $0.00 Strike: $38.16 | $0.00 |
DisclosureSEC source: 0000950170-24-069465 · ownership.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,542 Underlying: Common Shares · 15,542 shares Expires 2034-06-04 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 9,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015088 · form4-05312024_060514.xml · derivative · entry 4 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,387 Underlying: Common Stock · 9,387 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. F4 · derivative.expiration_date: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 15,959 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001415889-24-015088 · form4-05312024_060514.xml · derivative · entry 3 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,959 Underlying: Common Stock · 15,959 shares Expires 2034-05-28 F3 · derivative.exercise_date: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015088 · form4-05312024_060514.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. F2 · derivative.expiration_date: The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held. Read SEC document |
| May 29, 2024 Filed May 31, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015088 · form4-05312024_060514.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:09 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0000950170-24-029542 · ownership.xml · derivative · entry 4 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Shares · 20,000 shares Expires 2031-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-third of the total shares subject to the Option vested on the one year anniversary of the grant date, one-third of the total shares subject to the Option vested on the two year anniversary of the grant date, and one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:09 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,092 | $45.69 | $95,583.48 |
DisclosureSEC source: 0000950170-24-029542 · ownership.xml · nonDerivative · entry 3 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:09 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,408 | $46.16 | $64,993.28 |
DisclosureSEC source: 0000950170-24-029542 · ownership.xml · nonDerivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,092 F1 · price: Represents the closing price of the Company's common shares on March 7, 2024 for purposes of net settlement calculations. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:09 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 3,500 | $18.56 | $64,960.00 |
DisclosureSEC source: 0000950170-24-029542 · ownership.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 23:30 UTC | Alector, Inc. ALEC · Entity 6051 | GiftCommon Stock | 9,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068620 · ownership.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 Read SEC document |
| November 24, 2023 Filed Nov 28, 2023 22:32 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GiftCommon Stock | 2,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056827 · doc4.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,862 F1 · kind: Reflects the gift of common stock to a charitable donor advised fund. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:01 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 12,360 | $0.00 Strike: $7.71 | $0.00 |
DisclosureSEC source: 0000950170-23-028267 · ownership.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,360 Underlying: Common Stock · 12,360 shares Expires 2033-06-14 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 14, 2023, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:01 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-028267 · ownership.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,709 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:22 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 18,475 | $0.00 Strike: $38.96 | $0.00 |
DisclosureSEC source: 0000950170-23-026171 · ownership.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,475 Underlying: Common Shares · 18,475 shares Expires 2033-06-01 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034694 · doc4.xml · derivative · entry 8 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,652 Underlying: Common Stock · 6,652 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 11,045 | $0.00 Strike: $23.90 | $0.00 |
DisclosureSEC source: 0001209191-23-034694 · doc4.xml · derivative · entry 7 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,045 Underlying: Common Stock · 11,045 shares Expires 2033-05-31 F4 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 8,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034694 · doc4.xml · derivative · entry 6 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034694 · doc4.xml · nonDerivative · entry 3 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| September 29, 2022 Filed Jun 6, 2023 01:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034694 · doc4.xml · derivative · entry 5 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,919 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| September 29, 2022 Filed Jun 6, 2023 01:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,919 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034694 · doc4.xml · nonDerivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 21:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039829 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 23:18 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 18,918 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001209191-22-038536 · doc4.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,918 Underlying: Common Stock · 18,918 shares Expires 2032-06-16 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 16, 2022, or if earlier, the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 23:18 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 9,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038536 · doc4.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,459 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 16, 2023 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:21 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001209191-22-036947 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 13, 2022, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 00:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035670 · doc4.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,552 Underlying: Common Stock · 8,552 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 00:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 14,368 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001209191-22-035670 · doc4.xml · derivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,368 Underlying: Common Stock · 14,368 shares Expires 2032-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 6, 2023 01:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034694 · doc4.xml · derivative · entry 4 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 6, 2023 01:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034694 · doc4.xml · nonDerivative · entry 1 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:33 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058556 · doc4.xml · derivative · entry 2 GAROFALO ELIZABETH A. · CIK 0001826361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,919 Underlying: Common Stock · 1,918 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in two equal annual installments commencing September 29, 2021. F2 · derivative.expiration_date: The restricted stock units shall vest in two equal annual installments commencing September 29, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.